Adeia (NASDAQ:ADEA) makes its money in an unusual way: it does not build products, it licenses the ideas behind them. The company owns a large portfolio of patents covering technologies used in media and entertainment, the systems behind digital television, streaming, program guides and …
The Baltic Dry Index is not a stock price or aCommodityquote. It is a daily freight-rate benchmark published by the Baltic Exchange in London, tracking how much it costs to charter dry bulk ships carrying raw materials such as iron ore, coal, grain, bauxite, …
Alaunos Therapeutics (NASDAQ: TCRT) shares closed down 25% at $1.20 after the company announced a $1.12 million registered direct offering priced at $1.46 per share, utilizing common equity alongside pre-funded warrants to raiseCapitalintended for operational needs and general corporate uses.
Conduit Pharmaceuticals Inc. (NASDAQ: CDT) shares closed down 8% at $0.17 despite the company collaborating with QIMA Life Sciences to assess tapinarof combination therapies for autoimmune skin conditions.
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares closed down 31% at $39.75 after the company submitted a New Drug Application for azetukalner targeting focal onset seizures, backed by successful Phase 2b and Phase 3 trial results, while concurrently instituting a temporary enrollment pause across its …
Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares closed up 13% at $2.77 after the company entered into an all-stock acquisition agreement with Santersus AG, resulting in existing XBIO shareholders retaining roughly 15% ownership while Santersus investors secure the remaining 85% of the entity.
Cybin Inc. (NASDAQ: CYBN) shares closed down 12% at $12.37, even as the company was initiated with an Overweight rating by a Barclays analyst, who set a $35 price target on the equity.
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) shares closed up 10% at $1.23 after the company published peer-reviewed preclinical data evaluating Telomir-Zn in age-related macular degeneration, demonstrating regulated iron and copper levels, preserved retinal structure, improved visual metrics, and decreased mitochondrial oxidative stress in models.
OS Therapies Incorporated (NYSE: OSTX) reached regulatory consensus alongside European agencies regarding its adaptive Phase 3 framework evaluating OST-HER2 for resected pulmonary metastatic osteosarcoma.
InMed Pharmaceuticals Inc. (NASDAQ: INM) saw ADAR1 Capital Management acquire roughly $117,700 in common stock through open-market transactions.